A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination with Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients with Pancreatic Cancer

Brief description of study

We are conducting a clinical trial to test a new combination of four drugs for treating pancreatic cancer. Our research in the lab has shown that a certain protein called IL-1ß plays a role in the development of pancreatic cancer, and when we block this protein, it makes the cancer cells more sensitive to immunotherapy. We have already conducted a smaller study with a different immunotherapy drug (spartalizumab) and found that it can be safely combined with canakinumab, gemcitabine, and nab-paclitaxel in patients with advanced pancreatic cancer. Our initial results showed promise in treating this form of cancer, with additional tests performed on tissue and blood samples.




If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.